John Mascarenhas, MD, reviews JAK2 inhibitor options for patients with myelofibrosis, including pacritinib, ruxolitinib, and momelotinib.
Case: A 62-Year-Old Man with Myelofibrosis
Clinical Presentation:
Initial Clinical Workup and Diagnosis (Post-PCP Visit):
Current Treatments:
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More